Sareum - Specialists in Structure-based Drug Discovery
Print the page Smaller text Larger text

 

Pipeline – Aurora/FLT

 

About Aurora Kinases

Aurora kinases A and B are required for cells to both enter and proceed through mitosis, which is the process by which copies of the duplicated DNA chromosomes are segregated into two daughter cells. Moreover, Aurora kinases are over-expressed in a variety of cancers including pancreatic, ovarian, colon, breast, liver, lung, thyroid and bladder cancer. These cellular proteins therefore represent attractive targets for treating a wide range of cancers.

 

About FLT Kinases

The FLT kinases (FMS-like tyrosine kinases) have been demonstrated to be important in many stages of tumour development.

A dual Aurora/FLT inhibitor

A single drug inhibiting the enzyme activity of Aurora and one of the FLT kinases would be expected to exert its therapeutic effect by blocking more than one cause of cancer progression, ideally providing a more effective cancer therapy.

Sareum have produced novel inhibitors which inhibit both Aurora and FLT4 activity. These compounds are currently being optimised in order to produce drugs which reduce or ablate solid tumours whilst also preventing the spread of secondary tumours.

Disease Progression



Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader


site map

email: info@sareum.co.uk tel: +44 (0) 1223 497700 fax: +44 (0) 1223 497701